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Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic in the Netherlands it was noticed that
very few blood cultures from COVID-19 patients turned positive with clinically relevant bacteria. This was particularly
evident in comparison to the number of positive blood cultures during previous seasonal epidemics of influenza.
This observation raised questions about the occurrence and causative microorganisms of bacteraemia in COVID-19
patients, especially in the perspective of the widely reported overuse of antibiotics and the rising rate of antibiotic
resistance.
Methods: We conducted a retrospective cohort study on blood culture results in influenza A, influenza B and
COVID-19 patients presenting to two hospitals in the Netherlands. Our main outcome consisted of the percentage
of positive blood cultures. The percentage of clinically relevant blood cultures, isolated bacteria and 30-day all-cause
mortality served as our secondary outcomes.
Results: A total of 1331 viral episodes were analysed in 1324 patients. There was no statistically significant
difference (p = 0.47) in overall occurrence of blood culture positivity in COVID-19 patients (9.0, 95% CI 6.8–11.1) in
comparison to influenza A (11.4, 95% CI 7.9–14.8) and influenza B patients (10.4, 95% CI 7.1–13.7,). After correcting
for the high rate of contamination, the occurrence of clinically relevant bacteraemia in COVID-19 patients
amounted to 1.0% (95% CI 0.3–1.8), which was statistically significantly lower (p = 0.04) compared to influenza A
patients (4.0, 95% CI 1.9–6.1) and influenza B patients (3.0, 95% CI 1.2–4.9). The most frequently identified bacterial
isolates in COVID-19 patients were Escherichia coli (n = 2) and Streptococcus pneumoniae (n = 2). The overall 30-day
all-cause mortality for COVID-19 patients was 28.3% (95% CI 24.9–31.7), which was statistically significantly higher
(p = <.001) when compared to patients with influenza A (7.1, 95% CI 4.3–9.9) and patients with influenza B
(6.4, 95% CI 3.8–9.1).
Conclusions: We report a very low occurrence of community-acquired bacteraemia amongst COVID-19 patients in
comparison to influenza patients. These results reinforce current clinical guidelines on antibiotic management in
COVID-19, which only advise utilization of antibiotics when a bacterial co-infection is suspected.
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Introduction
In December 2019, the Wuhan Municipal Health Com-
mission in China reported a few cases of pneumonia
with an unknown aetiology. In these cases, the novel se-
vere acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was discovered [1, 2]. On February 27, 2020, the
first case of coronavirus disease 2019 (COVID-19) was
reported in the Netherlands [3]. After this first case, the
SARS-CoV-2 virus spread rapidly in the south of the
Netherlands. The southern region emerged as the Dutch
epicentre of the first wave of COVID-19, putting a large
strain on the microbiology laboratories in this area. Nu-
merous analyses of SARS-CoV-2 tests, blood cultures
and respiratory samples were performed. It was observed
that during this period very few blood cultures were
positive as a result of relevant bacteraemia, especially in
comparison to blood cultures collected during influenza
seasons. This raised questions about the occurrence of
bacteraemia and bacterial co-infections in COVID-19
patients.
Bacterial co-infections are frequently identified in
influenza infections and are an important cause of
morbidity and mortality [4, 5]. It is estimated that
11–35% of all patients with an influenza infection ac-
quire a bacterial co-infection [6]. The most frequently
isolated pathogens are Streptococcus pneumoniae,
Staphylococcus aureus and Haemophilus influenzae
[7]. Although the use of empiric antibiotics is only
recommended when a bacterial co-infection is sus-
pected, it is difficult for physicians to differentiate be-
tween a viral infection and bacterial co-infection [8,
9]. This contributes to a widely recognized overuse of
antibiotics in patients with viral infections [6, 10, 11].
For COVID-19, little is known about the occurrence
of bacterial co-infections and the causative pathogens.
One small observational study in the Netherlands
showed an overall co-infection rate of 16% in
COVID-19 patients [12]. Gaining more knowledge on
this subject is important, particularly when deciding on
the appropriate antibiotic regimen. During the first wave
of the COVID-19 pandemic, many patients received em-
piric antibiotics prior to and during their admission to the
hospital [13]. Numbers range from 31% in the
Netherlands to 95% in Asia [3, 14]. Cephalosporins and
broad-spectrum penicillins were most frequently pre-
scribed in the Netherlands [13]. Unnecessary use of antibi-
otics has many disadvantages, especially in the view of a
rising rate of antibiotic resistance [15].
Studying the occurrence, causative microorganisms
and outcome of bacteraemia in COVID-19 patients in
comparison to influenza A and B patients will increase
the knowledge about bacterial co-infections in COVID-
19 and possibly refine the current guidelines on anti-
biotic management.
Methods
Study design and population
We performed a retrospective cohort study of patients
with an influenza A, influenza B or a COVID-19 diagno-
sis and analysed blood culture outcomes. Patients were
enrolled from two different hospitals in the Netherlands,
the Jeroen Bosch Hospital in ‘s-Hertogenbosch and
Bernhoven Hospital in Uden. Patients were divided into
three cohorts according to their infection status: (1) pa-
tients with an influenza A diagnosis in the influenza sea-
son 2015/2016 or 2016/2017, (2) patients with an
influenza B diagnosis in influenza season 2017/2018 and
(3) patients with a COVID-19 diagnosis between 28 Feb-
ruary 2020 and 2 June 2020.
Patients were included when an influenza or a
COVID-19 infection was confirmed by reverse transcrip-
tion polymerase chain reaction (RT-PCR) on RNA from
oropharyngeal swabs (in case of influenza) or oronaso-
pharyngeal swabs (in case of COVID-19). Blood cultures
were collected within a time interval of 48 h before and
after the RT-PCR test.
Included into our analysis were patients attending the
emergency department, patients diagnosed with influ-
enza or COVID-19 at outpatients clinics who were sub-
sequently hospitalized and patients who developed fever
or flu-like symptoms during early hospitalization for
other medical reasons. Patients who were discharged
from the emergency department were analysed as well.
The following information was recorded and collected
in an anonymous database: demographic data, viral diag-
nosis, blood culture results, names of isolated bacteria,
likelihood of contamination, the hospital ward where the
blood culture was collected, blood culture collection
date and time and outcome of hospitalization expressed
as 30-day all-cause mortality. Predominantly the data
were extracted from the laboratory information system
(MOLIS). Only the outcome of hospitalization was
manually collected from the patient’s medical record.
Bacteria were categorized as likely contaminants if they
were affiliated to groups that represent commensal skin
microbiota and were defined in the patient’s medical
record as a contaminant by the Department of Medical
Microbiology [16].
The percentage of positive blood cultures served as
our primary outcome. Secondary outcomes were the
percentage of relevant blood cultures, causative microor-
ganisms and 30-day all-cause mortality.
This study was performed in line with the principles of
the Declaration of Helsinki. The board of directors of
both the Jeroen Bosch Hospital and Bernhoven Hospital
approved this study. Additional ethical approval was
granted by the Medical Ethical Review Committee Bra-
bant (METC Brabant). Due to the collected data being
held anonymously, informed consent was waived by the
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scientific review boards of both the Jeroen Bosch Hos-
pital and Bernhoven Hospital for this study. Patients
who had stated an objection to utilization of their med-
ical data for scientific research in their electronic med-
ical record were excluded from this study.
Data analysis
Categorical variables are displayed as frequencies and
percentages. Means and standard deviations were used
to report continuous variables. The categorical variables
were compared using the chi-square test or the Fisher’s
exact test. The continuous variables were compared
using a one-way analysis of variance (ANOVA). A p
value < 0.05 was considered statistically significant. All




We examined 1635 patients who had blood cultures
analysed and a diagnosis of either influenza A, influenza
B or COVID-19. Some patients appeared multiple times
in the list extracted from the laboratory information
system due to numerous positive tests for one virus
obtained during hospitalization. These patients were in-
cluded only once, at the time of presentation to the hos-
pital. Other patients were excluded due to blood
cultures not collected within 48 h of viral testing. In the
end, a total of 1324 patients were included. Seven pa-
tients were included twice due to being hospitalized with
two different viral infections during various viral seasons.
Therefore, the total number of viral episodes amounted
to 1331. Among these, there were 325 influenza A infec-
tions, 328 influenza B infections and 678 COVID-19
infections. Blood cultures were collected at the emer-
gency department in 88.2% of all viral episodes. There
were no differences between the cohorts regarding me-
dian age. The frequency of males was higher in the influ-
enza A cohort (58.2%) and in the COVID-19 cohort
(65.1%). Detailed demographics are listed in Table 1.
Bacteraemia and clinical outcomes
There was no statistically significant difference (p = 0.47,
Table 2) in the occurrence of blood culture positivity in
influenza A patients (11.4, 95% CI 7.9–14.8), influenza B
patients (10.4, 95% CI 7.1–13.7) and COVID-19 patients
(9.0, 95% CI 6.8–11.1). After correcting for likely con-
taminants, the occurrence of relevant bacteraemia in
COVID-19 patients declined to 1.0% (95% CI 0.3–1.8),
which was statistically significantly lower (p = 0.04) than
in influenza A patients (4.0, 95% CI 1.9–6.1) and influ-
enza B patients (3.0, 95% CI 1.2–4.9). COVID-19
patients with relevant bacteraemia were significantly
older (p = 0.03, Table 3) in comparison to patients
without bacteraemia. No significant difference in gender
was found in COVID-19 patients with relevant
bacteraemia and patients without bacteraemia. The over-
all 30-day all-cause mortality rate was significantly
higher (p = <.001, Table 4 in patients with COVID-19
(28.3, 95% CI 24.9–31.7) compared to patients with
influenza A (7.1, 95% CI 4.3–9.9) and patients with in-
fluenza B (6.4, 95% CI 3.8–9.1). When examining the
30-day mortality in patients with positive blood cultures,
a significantly higher mortality (p = 0.02, Table 4) was
found in patients in the influenza A cohort (18.9, 95%
CI 6.3–31.5) and patients in the COVID-19 cohort (26.2,
95% CI 15.2–37.3) compared to patients in the influenza
B cohort (2.9, 95% CI − 2.7-8.4). There was no statisti-
cally significant difference in 30-day all-cause mortality
between the different cohorts among patients with rele-
vant bacteraemia.








Male 189 (58.2) 162 (49.4) 443 (65.1)
Age (years), median (interquartile range) 71 (59–81) 74 (64–83) 70 (58–78)
Age categorized (years), n (%)
< 40 29 (9.0) 20 (6.1) 19 (2.8)
40–60 56 (17.2) 42 (12.8) 179 (26.3)
> 60 240 (73.8) 266 (81.1) 483 (70.9)
Presentation, n (%)
Emergency Department 292 (89.8) 272 (82.9) 613 (90.4)
Outpatient clinic 1 (0.3) 1 (0.3) 4 (0.6)
Nursing ward 31 (9.5) 52 (15.9) 55 (8.1)
Intensive care 1 (0.3) 3 (0.9) 6 (0.9)
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Causative microorganisms of bacteraemia
A total of 135 bacteria were isolated from 132 patients
with positive blood cultures in the different cohorts. Of
the 64 bacterial isolates in COVID-19 patients, 57
(89.1%) consisted of coagulase-negative staphylococci
and other bacterial species that can be regarded as con-
taminants. This percentage of contamination was higher
than in influenza A (64.9%) and influenza B patients
(70.6%).
Escherichia coli and S. pneumoniae were the most
common pathogens identified in patients with COVID-
19, each accounting for 28.6% (n = 2) of bacteria causing
a relevant bacteraemia. Other pathogens causing rele-
vant bacteraemia in COVID-19 patients were: S. aureus,
Klebsiella pneumoniae and Pseudomonas aeruginosa (all
n = 1). S. pneumoniae was the most common cause of
relevant bacteraemia among influenza A patients, caus-
ing 76.9% (n = 10) of all bloodstream infections in this
cohort. The most frequently isolated bacteria in influ-
enza B patients were S. pneumoniae and S. aureus, each
accounting for 40.0% (n = 4) of all isolated bacteria. No
bacteria seemed to be overrepresented in COVID-19
patients. The bacterial pathogens identified are further
detailed in Tables 5 and 6.
Discussion
Our study showed that only 1.0% of COVID-19 patients
presenting at a general hospital experienced a clinically
relevant bacteraemia, compared to 4.0% in influenza A
patients and 3.0% in influenza B patients. E. coli and S.
pneumoniae were most frequently isolated from positive
blood cultures in COVID-19 patients. The same patho-
gens were also common in influenza A and B patients.
We reported a 30-day all-cause mortality of 28.3% in
COVID-19 patients, which was statistically significantly
higher than the 30-day all-cause mortality of 7.1 and
6.4% found in respectively influenza A and B patients.
Our results are consistent with findings in a recent
study of Sepulveda et al. [17]. They performed a large
multicentre cohort analysis on patients with COVID-19
in New York. The authors reported a true bacteraemia
rate of 1.6%. The most common causative microorgan-
isms of bacteraemia in their study population were E.
coli, S. aureus, K. pneumoniae and Enterobacter cloacae
complex. A study of Hughes et al. also described similar
findings [18]. The authors reported an occurrence of
bacteraemia of 3.2%. This percentage consisted of both
hospital- and community-acquired infections. We only
reported on community-acquired infections, which may
explain the difference. Their most frequently isolated
community-acquired pathogens were Enterobacterales,
Streptococcus spp., S. aureus and Enterococcus spp. A re-
cent study of Goyal et al. noted a bacteraemia rate of
5.6% in COVID-19 patients [19]. This is significantly
higher than the 1.0% that our study reported. Like
Hughes et al., these authors examined both hospital-
acquired and community-acquired infections, which may
explain the higher rate of bacteraemia.
We reported a blood culture contamination rate of
89.1% amongst COVID-19 patients. This percentage is
fairly consistent with other studies [17, 18]. This high
percentage may be explained by the high workload and
the recruitment of more inexperienced health care
workers during the pandemic.
We found a 30-day all-cause mortality of 28.3% in our
COVID-19 cohort. This number is relatively high com-
pared to recent reports from Europe that describe 30-
day all-cause mortality rates ranging from 19.7 to 21.5%
[20, 21]. This disparity may be attributed to the higher
risk of severe disease in our study population. During







% (n) 95% CI % (n) 95% CI % (n) 95% CI p value**
Positive blood cultures 11.4 (37) 7.9–14.8 10.4 (34) 7.1–13.7 9.0 (61) 6.8–11.1 0.47
Relevant positive blood cultures* 4.0 (13) 1.9–6.1 3.0 (10) 1.2–4.9 1.0 (7) 0.3–1.8 0.04
* Corrected for contamination
** Pearson’s chi-squared test
95% CI = 95% confidence interval







Male 4 (57.1) 438 (65.3) 0.72*
Age (years), median (interquartile range) 83 (70–85) 70 (58–78) 0.03**
* Pearson’s chi-squared test
** One-way ANOVA
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the first wave of COVID-19, family doctors in our region
were asked to refer only severe cases to the overloaded
hospitals. Furthermore, we only included patients with
COVID-19 and analysed blood cultures. The required
collection of blood cultures suggests these patients expe-
rienced severe febrile illness which indicates more severe
disease.
Our findings on bacteraemia in influenza patients are
consistent with prior studies [22, 23]. We reported a
slightly lower rate of bacteraemia in influenza B patients
in comparison to influenza A patients. This is in
agreement with the assertion that influenza B often
leads to milder disease and less co-infections when
compared to influenza A [24, 25]. The 30-day all-
cause mortality rate amongst influenza patients in our
cohort was comparable to mortality rates mentioned
in other literature [20, 26].
Our findings support current guidelines on antibiotic
management that do not recommend the use of empiric
antibiotics in patients with COVID-19 unless there is a
clear suspicion of an accompanying bacterial infection
[8]. However, differentiating between viral disease and a
bacterial co-infection can be a challenge for physicians.
Procalcitonin levels may be of assistance in determining
the likelihood of bacterial co-infection and a potential
adverse outcome [27]. When a bacterial co-infection is
suspected and empiric antibiotics are administered, we
advise to regularly collect blood cultures and respiratory
samples. The antibiotic therapy may then be de-
escalated or completely terminated based on the micro-
biological results. These recommendations will help in
preventing overuse and the occurrence of potential side-
effects from antibiotics.
A major strength of our study is the inclusion of over
1300 patients from two different hospitals in the
Netherlands. This large sample size increases the accur-
acy and reliability of our results. In addition, we reported
on community-acquired infections. Most studies on bac-
terial co-infections in COVID-19 failed to report on the
setting of their study and possibly investigated hospital-
acquired infections as well, which negatively affects the
interpretability of their results [17, 28–30]. Finally, we
did not experience any missing data, which minimizes
the potential risk of information bias.
Some limitations should be mentioned. We did not
collect data on prior antibiotic use, which may have led
to an underestimation of the actual occurrence of bac-
teraemia in COVID-19 and influenza patients. Although
the sample size of this study was of a reasonably large
magnitude, the actual number of patients experiencing
relevant bacteraemia was quite low, subgroup analyses
Table 4 The 30-day all-cause mortality rate in patients with influenza A, influenza B or COVID-19 stratified by blood culture results
Influenza A Influenza B COVID-19
Mortality rate % (n) 95% CI % (n) 95% CI % (n) 95% CI p value
Overall 7.1 (23) 4.3–9.9 6.4 (21) 3.8–9.1 28.3 (192) 24.9–31.7 <.001**
With positive blood culture 18.9 (7) 6.3–31.5 2.9 (1) -2.7-8.4 26.2 (16) 15.2–37.3 0.02**
With relevant positive blood culture* 30.8 (4) 5.7–55.9 10.0 (1) −8.6-28.6 42.9 (3) 6.2–79.5 0.28***
* Corrected for contamination
** Pearson’s chi-squared test
*** Fisher’s exact test
95% CI = 95% confidence interval
Table 5 Bacteria isolated from positive blood cultures stratified
by infection status
Positive blood cultures






Escherichia coli 1 (2.7) 1 (2.9) 2 (3.1)
Klebsiella pneumoniae 1 (2.7) – 1 (1.6)
Pseudomonas aeruginosa – – 1 (1.6)
Micrococcus luteus 1 (2.7) – –
Streptococcus pneumoniae 10 (27.0) 4 (11.8) 2 (3.1)
Other Streptococcus species* 1 (2.7) 1 (2.9) 1 (1.6)
Staphylococcus aureus 1 (2.7) 4 (11.8) 1 (1.6)
CNS 20 (54.1) 23 (67.7) 55 (85.8)
Bacillus simplex 1 (2.7) – –
Brevibacterium casei – 1 (2.9) –
Corynebacterium species 1 (2.7) – 1 (1.6)
Total 37 (100) 34 (100) 64 (100)**
CNS = Coagulase-negative staphylococci
* Streptococcus salivarius, Streptococcus pyogenes, Streptococcus vestibularis
** Multiple bacteria were isolated from some of the blood cultures
Table 6 Bacteria isolated from positive blood cultures after
correcting for contamination, stratified by infection status
Positive blood cultures






Escherichia coli 1 (7.7) 1 (10.0) 2 (28.6)
Klebsiella pneumoniae 1 (7.7) – 1 (14.3)
Pseudomonas aeruginosa – – 1 (14.3)
Streptococcus pneumoniae 10 (76.9) 4 (40.0) 2 (28.6)
Streptococcus pyogenes – 1 (10.0) –
Staphylococcus aureus 1 (6.7) 4 (40.0) 1 (14.3)
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of the 30-day all-cause mortality are therefore unreliable.
In addition, we only reported on patients with bacter-
aemia and did not investigate other manifestations of
bacterial co-infections. Thus, these results do not repre-
sent the entirety of bacterial co-infections in influenza
and COVID-19 patients.
In conclusion, the proportion of clinically relevant
community-acquired bacteraemia in COVID-19 patients
was very low in comparison to influenza patients. These
results justify the prudent use of empiric antibiotics in
COVID-19 patients, when there is insufficient evidence
of a bacterial co-infection.
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